Pre-clinical drug prioritization via prognosis-guided genetic interaction networks.
The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Patient population heterogeneity and unpredictable physiology complicate pre-clinical cancer modeling efforts. We hypothesize that gene networks asso...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2978107?pdf=render |
id |
doaj-ed51adb8dcd34a97913430d9ee67b6cd |
---|---|
record_format |
Article |
spelling |
doaj-ed51adb8dcd34a97913430d9ee67b6cd2020-11-25T00:12:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-01-01511e1393710.1371/journal.pone.0013937Pre-clinical drug prioritization via prognosis-guided genetic interaction networks.Jianghui XiongJuan LiuSimon RaynerZe TianYinghui LiShanguang ChenThe high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Patient population heterogeneity and unpredictable physiology complicate pre-clinical cancer modeling efforts. We hypothesize that gene networks associated with cancer outcome in heterogeneous patient populations could serve as a reference for identifying drug effects. Here we propose a novel in vivo genetic interaction which we call 'synergistic outcome determination' (SOD), a concept similar to 'Synthetic Lethality'. SOD is defined as the synergy of a gene pair with respect to cancer patients' outcome, whose correlation with outcome is due to cooperative, rather than independent, contributions of genes. The method combines microarray gene expression data with cancer prognostic information to identify synergistic gene-gene interactions that are then used to construct interaction networks based on gene modules (a group of genes which share similar function). In this way, we identified a cluster of important epigenetically regulated gene modules. By projecting drug sensitivity-associated genes on to the cancer-specific inter-module network, we defined a perturbation index for each drug based upon its characteristic perturbation pattern on the inter-module network. Finally, by calculating this index for compounds in the NCI Standard Agent Database, we significantly discriminated successful drugs from a broad set of test compounds, and further revealed the mechanisms of drug combinations. Thus, prognosis-guided synergistic gene-gene interaction networks could serve as an efficient in silico tool for pre-clinical drug prioritization and rational design of combinatorial therapies.http://europepmc.org/articles/PMC2978107?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jianghui Xiong Juan Liu Simon Rayner Ze Tian Yinghui Li Shanguang Chen |
spellingShingle |
Jianghui Xiong Juan Liu Simon Rayner Ze Tian Yinghui Li Shanguang Chen Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. PLoS ONE |
author_facet |
Jianghui Xiong Juan Liu Simon Rayner Ze Tian Yinghui Li Shanguang Chen |
author_sort |
Jianghui Xiong |
title |
Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. |
title_short |
Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. |
title_full |
Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. |
title_fullStr |
Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. |
title_full_unstemmed |
Pre-clinical drug prioritization via prognosis-guided genetic interaction networks. |
title_sort |
pre-clinical drug prioritization via prognosis-guided genetic interaction networks. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2010-01-01 |
description |
The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Patient population heterogeneity and unpredictable physiology complicate pre-clinical cancer modeling efforts. We hypothesize that gene networks associated with cancer outcome in heterogeneous patient populations could serve as a reference for identifying drug effects. Here we propose a novel in vivo genetic interaction which we call 'synergistic outcome determination' (SOD), a concept similar to 'Synthetic Lethality'. SOD is defined as the synergy of a gene pair with respect to cancer patients' outcome, whose correlation with outcome is due to cooperative, rather than independent, contributions of genes. The method combines microarray gene expression data with cancer prognostic information to identify synergistic gene-gene interactions that are then used to construct interaction networks based on gene modules (a group of genes which share similar function). In this way, we identified a cluster of important epigenetically regulated gene modules. By projecting drug sensitivity-associated genes on to the cancer-specific inter-module network, we defined a perturbation index for each drug based upon its characteristic perturbation pattern on the inter-module network. Finally, by calculating this index for compounds in the NCI Standard Agent Database, we significantly discriminated successful drugs from a broad set of test compounds, and further revealed the mechanisms of drug combinations. Thus, prognosis-guided synergistic gene-gene interaction networks could serve as an efficient in silico tool for pre-clinical drug prioritization and rational design of combinatorial therapies. |
url |
http://europepmc.org/articles/PMC2978107?pdf=render |
work_keys_str_mv |
AT jianghuixiong preclinicaldrugprioritizationviaprognosisguidedgeneticinteractionnetworks AT juanliu preclinicaldrugprioritizationviaprognosisguidedgeneticinteractionnetworks AT simonrayner preclinicaldrugprioritizationviaprognosisguidedgeneticinteractionnetworks AT zetian preclinicaldrugprioritizationviaprognosisguidedgeneticinteractionnetworks AT yinghuili preclinicaldrugprioritizationviaprognosisguidedgeneticinteractionnetworks AT shanguangchen preclinicaldrugprioritizationviaprognosisguidedgeneticinteractionnetworks |
_version_ |
1725400067168272384 |